Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

Provided By PR Newswire

Last update: Oct 28, 2021

BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax^® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.